Form 4: Zynex Inc. CEO Thomas Sandgaard Receives Restricted Stock Award

Thomas Sandgaard, CEO and Chairman of Zynex Inc., was granted 2,563 shares of restricted stock on April 30, 2024, under the company's 2017 Stock Incentive Plan.

Summary

• Thomas Sandgaard, the President, CEO, and Chairman of Zynex Inc., received a restricted stock award on April 30, 2024.
• The award consists of 2,563 shares of Zynex Inc. common stock.
• These shares were granted under the company's 2017 Stock Incentive Plan.
• The restricted stock vests quarterly over a two-year period, starting one quarter from the grant date.
• Following the transaction, Sandgaard directly owns 21,630 shares of restricted stock awards that have not vested.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of restricted stock aligns the CEO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock awards are a common form of executive compensation in the medical device industry, aligning management incentives with shareholder value.

Comparison to Industry Standards

• Stock awards are a common practice among publicly traded companies to incentivize executives.
• The vesting schedule of two years is fairly standard, as many companies use three to four year vesting schedules.
• Comparing the size of the award to other medical device companies would require more data on Zynex's compensation structure and company size.

Stakeholder Impact

• Shareholders may view the stock award positively as it incentivizes the CEO to increase company value.
• Employees may see the award as a sign of the company's commitment to its leadership.

Key Dates